Patientswithsystemicsclerosis(SSc)developoftenacralulcers which are resistant to therapy and may result in gangrene and amputation. We investigated the effect s of iloprost infusion on the acral ulcers and necrosis in...Patientswithsystemicsclerosis(SSc)developoftenacralulcers which are resistant to therapy and may result in gangrene and amputation. We investigated the effect s of iloprost infusion on the acral ulcers and necrosis in patients with five pa tients with SSc and one with mixed connective tissue disease who had been previo usly treated with various modalities without improvement. All patients had Rayna ud phenomenon, acral ulcers and necrosis. Iloprost 25 μg per day was administer ed intravenously daily over six hours for ten consecutive days. Eight weeks late r all patients were treated with a second iloprost therapy cycle for five days. Two patients with severe ulceration received a third cycle until remission occur red. In all cases acral ulcers hea led com pletely and no patient relapsed durin g an observation period of 6 months.展开更多
文摘Patientswithsystemicsclerosis(SSc)developoftenacralulcers which are resistant to therapy and may result in gangrene and amputation. We investigated the effect s of iloprost infusion on the acral ulcers and necrosis in patients with five pa tients with SSc and one with mixed connective tissue disease who had been previo usly treated with various modalities without improvement. All patients had Rayna ud phenomenon, acral ulcers and necrosis. Iloprost 25 μg per day was administer ed intravenously daily over six hours for ten consecutive days. Eight weeks late r all patients were treated with a second iloprost therapy cycle for five days. Two patients with severe ulceration received a third cycle until remission occur red. In all cases acral ulcers hea led com pletely and no patient relapsed durin g an observation period of 6 months.
